Related references
Note: Only part of the references are listed.Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016
Birgitte K. Giersing et al.
VACCINE (2019)
Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity
Dania Zhivaki et al.
IMMUNITY (2017)
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
Judith Falloon et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells
B. Cortjens et al.
JOURNAL OF VIROLOGY (2017)
Universal vaccine against respiratory syncytial virus A and B subtypes
Jeong-Yoon Lee et al.
PLOS ONE (2017)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Animal models of respiratory syncytial virus infection
Geraldine Taylor
VACCINE (2017)
Ongoing developments in RSV prophylaxis: a clinician's analysis
Fariba Rezaee et al.
CURRENT OPINION IN VIROLOGY (2017)
Respiratory syncytial virus: prospects for new and emerging therapeutics
Patricia A. Jorquera et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2017)
Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model
Sandra Fuentes et al.
SCIENTIFIC REPORTS (2017)
Single- and multiple viral respiratory infections in children: disease and management cannot be related to a specific pathogen
Jerome O. Wishaupt et al.
BMC INFECTIOUS DISEASES (2017)
Rapid and sensitive real-time assay for the detection of respiratory syncytial virus using RT-SIBA®
Kevin E. Eboigbodin et al.
BMC INFECTIOUS DISEASES (2017)
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Laurent Detalle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein
Jia Meng et al.
JOURNAL OF VIROLOGY (2016)
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus. infection in lung transplant recipients
Jens Gottlieb et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2016)
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation
Christopher C. Stobart et al.
NATURE COMMUNICATIONS (2016)
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials
Lindsay Broadbent et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2015)
CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells
Tatiana Chirkova et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium
Remi Villenave et al.
JOURNAL OF VIROLOGY (2015)
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial
Katherine L. O'Brien et al.
LANCET INFECTIOUS DISEASES (2015)
An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice
Seyhan Boyoglu-Barnum et al.
VIROLOGY (2015)
Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures
Sara M. Johnson et al.
PLOS PATHOGENS (2015)
CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner
Kwang-Il Jeong et al.
PLOS ONE (2015)
Effects of Anti-G and Anti-F Antibodies on Airway Function after Respiratory Syncytial Virus Infection
Junyan Han et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2014)
Within-Host Whole-Genome Deep Sequencing and Diversity Analysis of Human Respiratory Syncytial Virus Infection Reveals Dynamics of Genomic Diversity in the Absence and Presence of Immune Pressure
Yonatan H. Grad et al.
JOURNAL OF VIROLOGY (2014)
Limited Type I Interferons and Plasmacytoid Dendritic Cells during Neonatal Respiratory Syncytial Virus Infection Permit Immunopathogenesis upon Reinfection
Stephania A. Cormier et al.
JOURNAL OF VIROLOGY (2014)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein
John T. Bates et al.
VIROLOGY (2014)
Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses
Tatiana Chirkova et al.
JOURNAL OF VIROLOGY (2013)
A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab′)2 Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice
Seyhan Boyoglu-Barnum et al.
JOURNAL OF VIROLOGY (2013)
RSV Immunoprophylaxis: Does the Benefit Justify the Cost?
H. Cody Meissner et al.
PEDIATRICS (2013)
Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein
Zhiwu Sun et al.
VIRUSES-BASEL (2013)
Development of asthma is determined by the age-dependent host response to respiratory virus infection: therapeutic implications
Erwin W. Gelfand
CURRENT OPINION IN IMMUNOLOGY (2012)
The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and Complement
Alexander Bukreyev et al.
JOURNAL OF VIROLOGY (2012)
Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma
Nandini Krishnamoorthy et al.
NATURE MEDICINE (2012)
Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab
Qing Zhu et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Palivizumab-Resistant Human Respiratory Syncytial Virus Infection in Infancy
Ortwin Adams et al.
CLINICAL INFECTIOUS DISEASES (2010)
Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
Ellen J. Collarini et al.
JOURNAL OF IMMUNOLOGY (2009)
Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice
Lia M. Haynes et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway
Christine M. Oshansky et al.
VIRAL IMMUNOLOGY (2009)
T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis
Virginia Amanatidou et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease
G Tal et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults
UF Power et al.
JOURNAL OF INFECTIOUS DISEASES (2001)